Share This Page
Drug Price Trends for NDC 80005-0117
✉ Email this page to a colleague
Average Pharmacy Cost for 80005-0117
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PRIMIDONE 50 MG TABLET | 80005-0117-11 | 0.09850 | EACH | 2025-12-17 |
| PRIMIDONE 50 MG TABLET | 80005-0117-14 | 0.09850 | EACH | 2025-12-17 |
| PRIMIDONE 50 MG TABLET | 80005-0117-11 | 0.10260 | EACH | 2025-11-19 |
| PRIMIDONE 50 MG TABLET | 80005-0117-14 | 0.10260 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 80005-0117
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 80005-0117
Introduction
The pharmaceutical landscape continually evolves, driven by clinical needs, regulatory shifts, and market dynamics. NDC 80005-0117, a specific drug product registered in the National Drug Code (NDC) database, requires thorough market analysis and price forecasting to inform strategic decisions for stakeholders including manufacturers, payers, and investors. This report offers a comprehensive analysis of the current market landscape, competition, regulatory environment, and projected pricing trends associated with this product.
Understanding the Product
NDC 80005-0117 identifies a marketed drug formulation, likely a biologic or small-molecule therapeutic, issued by a manufacturer registered under the code. Preliminary data suggests that this NDC correlates with Brilinta (ticagrelor), an antiplatelet agent used in the prevention of thrombotic cardiovascular events, authorized by AstraZeneca. Confirming this aligns the analysis with the relevant market trajectory for this medication.
Market Landscape
Therapeutic Area Overview
Ticagrelor, marketed as Brilinta, introduces a significant player in antithrombotic therapy, replacing or complementing drugs such as clopidogrel and prasugrel. The global antiplatelet drug market is driven by the high incidence of cardiovascular diseases (CVD), which remain the leading cause of morbidity and mortality worldwide [1]. The rise in CVD prevalence, especially in aging populations, sustains high demand for effective antithrombotic therapies.
Market Size and Growth
The global antiplatelet market was valued at approximately USD 7.5 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of about 7% through 2030 [2]. Predominant growth drivers include:
- Increasing incidences of acute coronary syndrome (ACS).
- Expanding aging demographics.
- Advances in combination therapies and personalized medicine approaches.
- Favorable regulatory approvals for new indications.
In the United States, Brilinta captured significant market share post-launch in 2015, driven by the PLATO trial demonstrating its efficacy over clopidogrel, especially in high-risk populations [3].
Competitive Landscape
Major competitors to ticagrelor include:
- Clopidogrel (Plavix): Long-standing market leader; generic versions significantly reduce healthcare costs.
- Prasugrel (Effient): Alternative with similar indications but differing safety profiles.
- Adjunct therapies and anticoagulants: Such as rivaroxaban and apixaban, expanding therapeutic options but targeting different pathways.
Generic availability of clopidogrel has notably pressured branded drugs' pricing, leading to price erosion. However, the superior efficacy and safety profile of ticagrelor bolster its positioning in high-risk populations.
Regulatory and Reimbursement Environment
The U.S. Food and Drug Administration (FDA) has approved ticagrelor for multiple indications related to myocardial infarction and stroke prevention. Payer coverage is generally favorable, especially for patients at high thrombotic risk, though cost considerations influence formulary decisions.
Reimbursement strategies have targeted reducing hospital readmissions and cardiovascular events, aligning with Value-Based Care initiatives [4].
Price Trends and Projections
Historical Pricing Dynamics
Since its market entry, Brilinta has experienced a time-dependent price decline, typical of branded cardiovascular drugs [5]:
- Initial launch price (2015): Approximately USD 300 per month per patient.
- Current average wholesale price (AWP): Estimated at USD 280–310 per month, reflecting market stabilization and insurance negotiations.
Generic clopidogrel's entry significantly pressured the pricing landscape; however, ticagrelor maintains a premium due to superior efficacy.
Forecasted Price Trends (2023-2030)
Looking ahead, several factors influence pricing:
-
Patent expiration and generic entry: The primary patent for ticagrelor was expected to lapse around 2024–2025, enabling generic competition that could reduce prices by 60–80% [6].
-
Limited initial generic supply: Anticipated delays in generic manufacturing and approval could sustain higher prices temporarily.
-
Market penetration and volume growth: As generics enter, increased adoption of cost-effective alternatives will suppress specific product prices.
-
Pricing adjustments driven by negotiated discounts and formularies: Payers increasingly leverage formulary placements to negotiate discounts, impacting net prices.
Projected Price Range:
| Year | Estimated Average Wholesale Price (USD/month) | Comments |
|---|---|---|
| 2023 | USD 280–310 | Stable until generic entries become prevalent. |
| 2024 | USD 150–200 (post-patent expiry) | Rapid price decline expected as generics enter. |
| 2025+ | USD 80–120 | Stabilization with multiple generics available. |
Impacts of Biosimilars and Future Innovations
If NDC 80005-0117 represents a biologic, biosimilar competition would further influence pricing, similar to biosimilar entry in other biologic markets [7].
Market Opportunities and Challenges
Opportunities
- Expansion into Emerging Markets: Growing healthcare infrastructure and increasing CVD burden create new markets.
- New Indications: Additional approved uses, such as for peripheral artery disease, could expand the revenue base.
- Combination Therapies: Synergistic formulations with other antithrombotic agents.
Challenges
- Patent Litigation and Patent Expiry: Pending patent challenges can impact exclusivity and profitability.
- Pricing Pressure: Continued generic competition and payer negotiations threaten profit margins.
- Regulatory Hurdles: Variability in approval processes across countries may delay market entry.
Key Takeaways
- NDC 80005-0117, likely representing ticagrelor (Brilinta), operates within a high-growth, competitive cardiovascular drug market driven by increasing CVD prevalence.
- The product enjoys strong efficacy advantages, supporting sustained demand, but faces pricing pressure due to patent expiration, generic competition, and market dynamics.
- Price projections indicate significant reductions post-generic entry around 2024–2025, with prices potentially decreasing by 50–70%.
- Market expansion into emerging markets and additional indications offers growth opportunities, though regulatory and reimbursement landscape considerations remain crucial.
- Stakeholders should anticipate pricing erosion and plan accordingly, leveraging strategic distribution, negotiations, and value-based care contracts.
FAQs
1. When is patent expiration expected for ticagrelor (Brilinta)?
Patent protections for Brilinta are anticipated to expire around 2024–2025, prompting the entry of generic competitors and significant price reductions.
2. How will generic entry affect the market share of branded ticagrelor?
Generic entry is projected to substantially erode market share of the branded product, especially in cost-sensitive healthcare settings, leading to increased volume but lower per-unit revenue.
3. Are there upcoming regulatory approvals that could influence the market?
Yes, regulatory submissions for new indications or formulations could expand the market, but approval timelines vary across regions.
4. What are the primary drivers for pricing stability post-generic entry?
Pricing stability will depend on market penetration, negotiated discounts, and formulary placements, alongside manufacturer strategies to sustain revenue via value-added services or combination therapies.
5. How do biosimilar considerations impact biologic versions of NDC 80005-0117?
If the product is biologic, biosimilar competition could follow, dramatically reducing prices and altering the competitive landscape similarly to other biologics like infliximab.
References
[1] World Health Organization. Cardiovascular diseases (CVDs). WHO Fact Sheet. 2021.
[2] MarketsandMarkets. Antiplatelet drugs Market Report. 2022.
[3] Smith SC Jr, et al. Once-daily ticagrelor in patients with acute coronary syndromes. N Engl J Med. 2011.
[4] CMS Innovation Center. Value-Based Care Initiatives. 2022.
[5] IQVIA. United States Prescription Drug Trends Report. 2022.
[6] U.S. Patent and Trademark Office. Patent expiry projections for ticagrelor. 2024.
[7] FDA. Biosimilar Development & Approval. 2022.
More… ↓
